# Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

> **NCT00890500** · PHASE1 · COMPLETED · sponsor: **Fate Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Hematologic Malignancies
- Allogeneic Stem Cell Transplantation

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Antithymocyte Globulin
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00890500
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-05
- **Final completion:** 2013-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2013-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890500, "Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00890500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*